The Role of Complement in the Immunologic Microenvironment of Tumor Cells: Potential Therapeutic Targets

키워드

참고문헌 (52)

1. Austin EB, "Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T", 36. J, 1989, pp.67, 525~530
2. Bu X, "Significance of C4d deposition in the follicular lymphoma and MALT lymphoma and their relationship with follicular dendritic cells", Pathol. Res. Pract, 203, pp.163~167 (2007)
3. Bureeva S, "Drug design using the example of the complement system inhibitors' development", Drug Discov. Today, 10, pp.1535~1542 (2005)
4. Cheung NK, "Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro", J. Clin. Invest, 81, pp.1122~1128 (1988)
5. Cimino-Mathews A, "Immune targeting in breast cancer", Oncology, 29, pp.375~385 (2015)
6. Corrales L, "Anaphylatoxin c5a creates a favorable microenvironment for lung cancer progression", J. Immunol, 189, pp.4674~4683 (2012)
7. Davis AE, "C1 inhibitor, a multi-functional serine protease inhibitor", Thromb. Haemost, 104, pp.886~893 (2010)
8. Donin D, "Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid", Clin. ExpImmunol, 131, pp.254~263 (2003)
9. Dougan M, "Immune therapy for cancer", Annual Rev. Immunol, 27, pp.83~117 (2009)
10. Durrant LG, "Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients", Cancer. Immunol. Immunother, 52, pp.638~642 (2003)
11. (2013)[URL]
12. Fishelson Z, "Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors", Mol. Immunol, 40, pp.109~123 (2003)
13. Gasque P, "Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins", J. Neuroimmunol, 66, pp.29~40 (1996)
14. Gmiński J, "Immunoglobulins and complement components levels in patients with lung cancer", Rom. J. Intern. Med, 30, pp.39~44 (1992)
15. Gunn L, "Opposing roles for complement component C5a in tumor progression and the tumor microenvironment", J. Immunol, 189, pp.2985~2994 (2012)
16. Guo RF, "Role of C5a in inflammatory responses", Annu. Rev. Immunol, 23, pp.821~852 (2005)
17. Guo Y, "Interleukin-6 signaling pathway in targeted therapy for cancer", Cancer Treat. Rev, 38, pp.904~910 (2012)
18. Janssen BJ, "Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition", J. Biol. Chem, 282, pp.29241~29247 (2007)
19. Kempshall E, "Complement-induced protection: an explanation for the limitations of cell-based tumour immunotherapies", Immunol. Cell Biol, 90, pp.869~871 (2012)
20. Kolev M, "Complement in cancer and cancer immunotherapy", Arch. Immunol. Ther. Exp, 59, pp.407~419 (2011)
21. Kraus S, "Cell densensitization by sublytic C5Bb-9 complexes and calcium ionophores depends on activatin of protein kinase C", Eur. J. Immunol, 30, pp.1272~1280 (2000)
22. Kraus S, "Involvement of the ERK mitogen-activated protein kinase in cell resistance to complementmediated lysis", Clin. ExpImmunol, 123, pp.366~374 (2001)
23. Kraut EH, "Alternative pathway of complement in multiple myeloma", Am. J. Hematol, 11, pp.335~345 (1981)
24. Kuraya M, "Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis", Eur. J. Immunol, 22, pp.1871~1876 (1992)
25. Lucas SD, "Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma", Hum. Pathol, 27, pp.1329~1335 (1996)
26. Maness PF, "Serum complement levels in patients with digestive tract carcinomas and other neoplastic diseases", Oncology, 34, pp.87~89 (1977)
27. Markiewski MM, "The role of complement in inflammatory diseases from behind the scenes into the spotlight", Am. J. Pathol, 171, pp.715~727 (2007)
28. Markiewski MM, "Is complement good or bad for cancer patients? A new perspective on an old dilemma", Trends Immunol, 30, pp.286~292 (2009)
29. Markiewski MM, "Modulation of the antitumor immune response by complement", Nat. Immunol, 9, pp.1225~1235 (2008)
30. McConnell I, "Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells", Eur. J. Immunol, 8, pp.453~458 (1978)
31. Morgan BP, "Complement, a target for therapy in inflammatory and degenerative disease", Nat. Rev. Drug Discov, 14, pp.857~877 (2015)
32. Niculescu F, "Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase", Atherosclerosis, 142, pp.47~56 (1999)
33. Niculescu F, "Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent", J. Immunol, 158, pp.4405~4412 (1997)
34. Niculescu F, "Persistent complement activation on tumor cells in breast cancer", Am. J. Pathol, 140, pp.1039~1043 (1992)
35. Nishioka K, "The complement system in tumor immunity: significance of elevated levels of complement in tumor bearing hosts", Ann. N Y Acad. Sci, 276, pp.303~315 (1976)
36. Nunez-Cruz S, "Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization", Neoplasia, 14, pp.994~1004 (2012)
37. Pio R, "Complement inhibition: promising concept for cancer treatment", Semin. Immunol, 25, pp.54~64 (2013)
38. Ricklin D, "Complement:a key system for immune surveillance and homeostasis", Nat. Immunol, 11, pp.785~797 (2010)
39. Ricklin D, "Complement-targeted therapeutics", Nat. Biotechnol, 25, pp.1265~1275 (2007)
40. Rutkowski MJ, "Cancer and the complement cascade", Molecul. Cancer Res, 8, pp.1453~1465 (2010)
41. Sahu A, "Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics", Immunopharmacology, 49, pp.133~148 (2000)
42. Sahu A, "Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3", MolImmunol, 39, pp.557~566 (2003)
43. Spendlove L, "A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions", Eur. J. Immunol, 30, pp.2944~2953 (2000)
44. Spiller OB, "Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack", Clin. ExpImmunol, 121, pp.234~241 (2000)
45. Swann JB, "Immune surveillance of tumour", J. Clin. Invest, 117, pp.1137~1146 (2007)
46. Szebeni J, "he complement system: Novel Roles in Health and Disease", pp.265~304 (2004), Kluwer Academic Publishers
47. Teeling JL, "The biological activity of human CD20monoclonal antibodies is linked to unique epitopes on CD20", J. Immunol, 177, pp.362~377 (2006)
48. Tegla CA, "Membrane attack by complement: the assembly and biology of terminal complement complexes", Immunol. Res, 51, pp.45~60 (2011)
49. Vagas-Madrazo E, "Canonical structure repertoire of the antigen-binding site of immunoglobulins suggests strong geometrical restrictions associated to the mechanism of immune recognition", J. Mol. Biol, 254, pp.497~504 (1995)
50. Woodruff TM, "Inhibiting the C5-C5a receptor axis", MolImmunol, 48, pp.1631~1642 (2011)
51. Ytting H, "Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer", Scand J. Gastroenterol, 39, pp.674~679 (2004)
52. Zipfel PF, "Complement regulators and inhibitory proteins", Nat. Rev. Immunol, 9, pp.729~740 (2009)

관련 논문AI추천